drugset / Trial / NCT04855721
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3)
Timeline
- Start
- 2021-05-04
- Primary completion
- 2022-11-30
- Completion
- 2022-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AUR101 | Unknown | 200 mg | Oral |
| Subject | AUR101 | Unknown | 400 mg | Oral |